Glaxosmithkline Stock News

GlaxoSmithKline (GSK) paused a late stage trial of its potential respiratory syncytial virus ((RSV)) vaccine candidate in pregnant women based on safety assessment by an…

Las Vegas, USA, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aerosol Delivery Devices Market to Grow to Whopping USD 44.07 billion at a Significant CAGR of 5.38% by 2026, Examines DelveInsight The Aerosol Delivery Devices market is gaining momentum owing to the rapidly rising cases of respiratory disorders such as Asthma, Chronic Obstructive Pulmonary Disorders (COPD), and others. Moreover, decreasing air quality in industrialized areas due to increasing air pollution is also a key factor driving the Aerosol Delivery Devices market. In addition, the growing adoption of digital technology by key market players to provide better respiratory disorder management solutions along with the increase in product approvals will contribute to the Aerosol Delivery Devices market growth. DelveInsight''s Aerosol Delivery Devices Market Insights and Forecast report provides the current and forecast Aerosol Delivery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers, and barriers, market trends, and key competitors in the Aerosol Delivery Devices Market.

In today’s recent session, 1.12 million shares of the GlaxoSmithKline plc (NYSE:GSK) have been traded, and its beta is 0.70. Most recently the company’s share price was $43.37, and it changed around -$0.25 or -0.57% from the last close, which brings the market valuation of the company to $110.05B. GSK at last check was trading … GlaxoSmithKline plc (NYSE: GSK): It Is A Stock Worth Considering Today Read More »

GlaxoSmithKline (GSK) has will limit its medications purchased at prices under the federal government 340B drug discount program to certain safety net hospital covered entities.

WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics license applications is expediting market growth. Primarily driven by favourable effective biopharmaceutical medications developed as a targeted therapy for cancer therapy, the total global Antibody Drug Conjugates (ADCS) Market is estimated to reach USD 13.17 Billion by 2028. The Market valued at a revenue of USD 4.24 Billion in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 18.9%. Furthermore, the rising benefit of Antibody Drug Conjugates (ADCS) as the unharmed healthy cells enable patients to recover quickly, thus growth of the Global Antibody Drug Conjugates (ADCS) Market, states Vantage Market Research, in a report, titled " Antibody Drug Conjugates (ADCS) Market by Application (Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer, Blood Cancer), by Technology (Cleavable Linker, Non-Cleavable Linker, Linkerless), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Researchers from GlaxoSmithKline (GSK) say that they are on the verge of a breakthrough in creating the world’s first vaccine against the deadly RSV. Within months, the world could have the data needed for a vaccine that targets the deadly virus that hospitalises and kills thousands of Britons every winter. RSV particularly affects children and […] Vaccine breakthrough: UK’s GSK to save thousands of lives with world’s first RSV jab

Monday''s top analyst upgrades and downgrades included Chewy, Cloudflare, Coca-Cola, Doximity, Ideanomics, GlaxoSmithKline, Micron Technology, SoFi Technologies, Teladoc Health, Twitter and Walmart.

Teva struck out Friday in its effort to convince a U.S. appeals court to rehear its arguments for undoing a $235 million verdict for GlaxoSmithKline in a patent fight over the heart drug Coreg.

GlaxoSmithKline (GSK) is speculated to be potentially targeting an acquisition of Theravance Biopharma (TBPH). The "rumour mill" is talking about a potential GSK bid for Theravance

DUBLIN , Feb. 10, 2022 /PRNewswire/ -- The "Oral Hygiene Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com''s offering. The global oral hygiene market reached a value of US$ 46.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 58.9 Billion by 2027, exhibiting a CAGR of 3.8% during 2022-2027. Keeping in mind the uncertainties of COVID-19, they are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor Oral hygiene refers to the practice of maintaining a clean and healthy mouth that is free from diseases and other oral problems. It is extremely important for all individuals to practice oral hygiene regularly to prevent dental issues, including tooth decay, gingivitis and periodontitis. It includes personal dental care routines with products, such as dental floss, breath fresheners, toothbrush, toothpaste and mouthwash.

Riot in ranks sends ‘strong message’ against tilt at GlaxoSmithKline’s consumer division

Shares of CureVac gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline . The open-label study plans to enroll 240 adults. CureVac had previously tried to develop a COVID-19 vaccine but instead decided last year to scrap those plans and instead focus on developing a second-generation COVID-19 shot with GSK. CureVac''s stock has tumbled 83.7% over the past year, while the broader S&P 500 is up 17.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Under-pressure Unilever CEO Alan Jope today tried to placate restless investors with “red meat” offerings as he tries to move on from a botched bid for GlaxoSmithKline ’s consumer healthcare business.

GlaxoSmithKline (GSK) said Chinas National Medical Products Administration approved Benlysta (belimumab) to treat adult patients with active lupus nephritis ((LN)) who are

GlaxoSmithKline (GSK) Vir Biotechnology (VIR) said preclinical data suggested that their COVID-19 therapy sotrovimab retained neutralizing activity against the BA.2 subvariant